anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In patients with a reduced left ventricular (LV) systolic function (ejection fraction < 35%) and a left bundle branch block with a QRS duration > 130 ms, cardiac resynchronization therapy (CRT) can contribute to an improvement in the quality of life and a reduction in mortality. The resynchronization is mostly achieved by pacing via an epicardial LV lead in the coronary sinus; however, this approach is often limited by the patient's venous anatomy and an increase in the stimulation threshold over time. In addition, up to 30% of patients do not respond to the intervention. New treatment approaches involve direct stimulation of the conduction system by pacing of the bundle of His or left bundle branch. This enables a more physiological propagation of the stimulus. Pacing of the left bundle branch is achieved by advancing the lead into the right ventricle and screwing it deep into the interventricular septum. Due to the relatively large target area of the left bundle branch the success rate is very high (currently > 90%). Observational studies have shown a greater reduction in the QRS duration, a more pronounced improvement in systolic function and a lower hospitalization rate for heart failure associated with conduction system pacing compared to CRT using a coronary sinus lead. These findings have been confirmed in small randomized trials. Therefore, the use of left bundle branch pacing should be considered not only as a bail out in the case of failed resynchronization using coronary sinus lead placement but increasingly also as an initial pacing strategy. The results of the first large randomized trials are expected to be released in late 2024.
Demyelination is a common pathological feature in a wide range of diseases, characterized by the loss of myelin sheath and myelin-supporting oligodendrocytes. These losses lead to impaired axonal function, increased vulnerability of axons to damage, and result in significant brain atrophy and neuro-axonal degeneration. Multiple pathomolecular processes contribute to neuroinflammation, oligodendrocyte cell death, and progressive neuronal dysfunction. In this study, we use the cuprizone mouse model of demyelination to investigate long-term non-invasive gamma entrainment using sensory stimulation as a potential therapeutic intervention for promoting myelination and reducing neuroinflammation in male mice. Here, we show that multisensory gamma stimulation mitigates demyelination, promotes oligodendrogenesis, preserves functional integrity and synaptic plasticity, attenuates oligodendrocyte ferroptosis-induced cell death, and reduces brain inflammation. Thus, the protective effects of multisensory gamma stimulation on myelin and anti-neuroinflammatory properties support its potential as a therapeutic approach for demyelinating disorders.
FFR has been introduced for the determination of physiological ischemia in the myocardium for many years. Nowadays, FFR-guided PCI is highly recommended for the assessment of physiologic ischemia in intermediate coronary lesions. FFR-guided PCI has been performed in National Taiwan University Hospital(NTUH) for many years. Nevertheless, the method of FFR measurement in NTUH is different from that in literature. In this study, the investigator would like to evaluate the effectiveness and safety of NTUH experience in FFR prospectively. First, the investigator will record any intracoronary (IC) injected adenosine-related complications, such as bradyarrhythmia or chest discomfort. Second, the investigator will follow up on the clinical outcome of the participants for 2 years, record if any target lesion failure, target vessel failure, target vessel-related myocardial infarction, and cardiac death. Finally, left ventricular diastolic pressure, serum pro-brain natriuretic peptide (pro-BNP), and high sensitivity C- reactive protein (hsCRP) will be checked and determined their relationships with the maximum dosage of IC adenosine.
The present invention provides a colloidal phase diagram: the phase separation temperature (TPh), the spinodal temperature (Tmeta), and the gelation temperature (Tgei). The TGM method provides a new approach to measure the latter two phase transitions (Tmeta and Tgei). By employing microfluidics sample chips, these phase transition temperatures can be measured for dozens of samples in a single experiment. These two-dimensional array assays facilitate rapid measurements of colloidal phase diagrams and excipient screens (e.g. PEG, salt, and pH titrations). The rate constants of ATPS formation can be determined for a continuum of temperatures along the temperature gradient of a given sample. Analysis of the temperature-dependent kinetics of ATPS formation provides new metrics for ATPS formation and gelation. These metrics include apparent attempt frequencies (Aapp), apparent activation energies (Ελ,αρρ). Moreover, a novel two-step mechanism was developed to assign the apparent activation energy for ATPS formation to distinct steps of the phase separation. In particular, the value of the apparent activation energy in the metastable region of the phase diagram was related to the energy needed to dissociate a protein from a droplet (EA,-I). Moreover, the apparent activation energy for ATPS formation in the spinodal region of the phase diagram could be assigned to the barrier to two droplets coalescing into one (EA,2). The use of Erying theory is also demonstrated, as opposed to Arrhenius theory, to extract transition state enthalpies (AH$) and entropies (AS*) for these processes. Samples that form gels at lower temperatures could also be analyzed by the V ogel -F ulcher-T amman law. This analysis yields information on the mechanical strength of mAh gels (fragility index, D), the ideal gelation temperature (To), and the intrinsic time constant for ATPS formation at higher temperatures (T0). The application of these theories to TGM technology offers a novel approach for determining these parameters.
Lymphomas are a heterogeneous group of diseases that originate from T, B or natural killer cells. Lymphoma treatment is based on chemotherapy, radiotherapy, and monoclonal antibody (mAb) or other immunotherapies. The P-selectin glycoprotein ligand 1 (PSGL-1) is expressed at the surface of hematological malignant cells and has been shown to have a pro-oncogenic role in multiple myeloma and lymphoma. Here, we investigated the expression and therapeutic potential of PSGL-1 in T and B cell lymphomas. By flow cytometry analysis, we found that PSGL-1 was expressed in both T and B cell-derived lymphoma cell lines but generally at higher levels in T cell lymphoma cell lines. For most T and B cell-derived lymphoma cell lines, in vitro targeting with the PL1 mAb, which recognizes the PSGL-1 N-terminal extracellular region and blocks functional interactions with selectins, resulted in reduced cell viability. The PL1 mAb pro-apoptotic activity was shown to be dose-dependent, to be linked to increased ERK kinase phosphorylation, and to be dependent on the MAP kinase signaling pathway. Importantly, anti-PSGL-1 treatment of mice xenografted with the HUT-78 cutaneous T-cell lymphoma cell line resulted in decreased tumor growth, had no effect on in vivo proliferation, but increased the levels of apoptosis in tumors. Anti-PSGL-1 treatment of mice xenografted with a Burkitt lymphoma cell line that was resistant to anti-PSGL-1 treatment in vitro, had no impact on tumorigenesis. These findings show that PSGL-1 antibody targeting triggers lymphoma cell apoptosis and substantiates PSGL-1 as a potential target for lymphoma therapy.
The most common blast-induced traumatic brain injury (bTBI)-associated problems are cognitive deficits, such as executive functioning and memory. This study evaluates a combined rehabilitation program: transcranial magnetic stimulation (TMS) and cognitive therapy for treatment of patients with bTBI. TMS is a noninvasive way of stimulating the brain, which is not painful and does not involve any needles or any form of surgery. It acts by delivering a magnetic stimulation to a particular brain region. Half of the study participants will receive cognitive intervention with active TMS, and a control group will receive cognitive intervention with sham TMS. This study takes place in Boston, Massachusetts: at the VA Boston Healthcare System and Beth Israel Deaconess Medical Center.
OBJECTIVES: I. Establish the feasibility of treating patients with persistent or platinum refractory stage III or IV ovarian cancer with sequential high dose chemotherapy followed by peripheral blood stem cell rescue. II. Determine the maximum tolerated dose of thiotepa that can be given in such approach.

OUTLINE: This is a dose escalating study of thiotepa. Initial cytoreduction and mobilization of peripheral blood stem cells (PBSC) are conducted with FHCRC protocol 506.3 (cyclophosphamide and paclitaxel) or 506.3 (cyclophosphamide and etoposide). PBSC from syngeneic twins are collected according to FHCRC protocol 753.0. Patients then undergo leukapheresis. Patients with remaining bulky disease (greater than 2 cm) after cytoreduction/mobilization may undergo surgical debulking. High dose chemotherapy begins 30-40 days after the last chemotherapy in the cytoreduction/mobilization regimen. Patients receive mitoxantrone IV infusion over 15 minutes on days -7 and -5. Thiotepa IV is administered on days -4 and -3. Peripheral blood stem cell (PBSC) infusion occurs on day 0. 60-90 days later, melphalan IV is administered over 60 minutes on day -3. Patients undergo PBSC infusion on day 0. Patients are entered in cohorts of 3. In the absence of dose-limiting toxicity (DLT), subsequent cohorts of 3 patients each receive escalating doses of thiotepa on the same schedule. If DLT is observed in 2 of 3 patients, then the next cohort of patients each receive treatment at the next lower dose level. Once 12 patients are treated at a particular dose level, then this dose is declared the maximum tolerated dose. After engraftment following melphalan, patients receive oral tamoxifen twice a day for up to 5 years or until relapse. Patients are followed every 3 months for the first year, every 6 months for the next 4 years, then annually.

PROJECTED ACCRUAL: 20-30 patients will be accrued in 2 years.
The invention provides a dog-skin plaster and a preparation technique thereof. The dog-skin plaster is made from a substrate and raw herbal materials of black-plaster dog-skin plasters. The mass ratio of the raw herbal materials is the same as the mass ratio in the prescription of the black-plaster dog-skin plaster. A processed radix aconiti replaces an unprocessed radix aconiti, and a processed kusnezoff monkshood root replaces an unprocessed kusnezoff monkshood root, wherein no lead is contained. The preparation uses an ethanol extracting technology and a volatile-oil extracting technique to replace the extracting technology of frying vegetable oil in the original preparation, which can completely extract drug ingredients, without such disadvantages as drug ingredients being easily destroyed by high temperature and air pollution which are generated by the extracting technique of frying vegetable in the original preparation; the new substrate replaces the original black-plaster substrate, which has the advantages of larger drug quantity, easy putting up and off, good compatibility, release property and skin penetration property, without toxic lead content. The unprocessed radix aconiti and the unprocessed kusnezoff monkshood root in the original prescription are replaced respectively by the processed radix aconiti and the processed kusnezoff monkshood root, thus ensuring the effectiveness and safety of the preparation and eliminating the skin sensitization caused by the original dog-skin plaster.
BACKGROUND: The Australian Clinical Practice Guidelines for Pregnancy Care recommend that during the first and subsequent antenatal visits all pregnant women are weighed; advised of recommended gestational weight gain (GWG), dietary intake and physical activity; and offered referrals for additional support if needed. The extent to which these recommendations are implemented and women's acceptability of recommended care is unknown. This study examines women's reported receipt and acceptability of guideline care for GWG, and characteristics associated with receipt of such care and its acceptability.
METHODS: From September 2018 to February 2019 a telephone survey was undertaken with women who had recently had a baby and received antenatal care from five public maternity services within a health district in Australia. Women self-reported their demographic characteristics, and receipt and acceptability of recommended GWG care. Receipt and acceptability of such care, and their association with the characteristics of women and the maternity service they attended, were examined using descriptive statistics and multivariable logistic regression analyses.
RESULTS: Of 514 women, 13.1% (95%CI:10.3-16.5) reported that they received an assessment of weight at both their first and a subsequent antenatal visit, and less than one third (30.0%; 95%CI:26.0-33.9) received advice on their recommended GWG range, dietary intake and physical activity. Just 6.6% (95%CI:4.8-9.1) of women reported receiving all assessment and advice components of recommended antenatal care, and 9.9% (95%CI:7.6-12.8) of women reported being referred for extra support. Women who were younger (OR = 1.13;95%CI:1.05-1.21), identifying as Aboriginal and Torres Strait Islander (OR = 24.54;95%CI:4.98-120.94), had a higher pre-pregnancy BMI (OR = 1.13;95%CI:1.05-1.21), were experiencing their first pregnancy (OR = 3.36;95%CI:1.27-8.86), and lived in a least disadvantaged area (compared to mid-disadvantaged area (OR = 18.5;95%CI:2.6-130.5) and most disadvantaged area (OR = 13.1;95%CI:2.09-82.4)) were more likely to receive recommended assessment and advice. Most Aboriginal (92%) and non-Aboriginal (93%) women agreed that recommended GWG care is acceptable.
CONCLUSION: Most women perceive antenatal care for GWG as recommended by the Clinical Practice Guidelines as acceptable, but did not receive it. When provided, such care is not delivered consistently to all women regardless of their characteristics or those of the maternity service they attend. There is a need for service-wide practice change to increase routine GWG care in pregnancy for all women.
OBJECTIVE: Indirect carotid-cavernous fistulas (CCFs) are abnormal arteriovenous shunting lesions with a highly variable clinical presentation that depends on the drainage pattern. Based on venous drainage, treatment can be either transarterial (TA) or transvenous (TV). The aim of this study was to compare the outcomes of indirect CCF embolization via the TA, TV, and direct superior ophthalmic vein (SOV) approaches.
METHODS: The authors conducted a retrospective analysis of 74 patients admitted to their institution from 2010 to 2023 with the diagnosis of 77 indirect CCFs as confirmed on digital subtraction angiography.
RESULTS: A total of 74 patients with 77 indirect CCFs were included in this study. Embolization was performed via the TA approach in 4 cases, the TV approach in 50 cases, and the SOV in 23 cases. At the end of the procedure, complete occlusion was achieved in 76 (98.7%) cases. The rate of complete occlusion at the end of the procedure and at last radiological follow-up was significantly higher in the SOV and TV cohorts than in the TA cohort. The rate of recurrence was highest in the TA cohort (25% for TA vs 5.3% for TV vs 0% for SOV, p = 0.68).
CONCLUSIONS: The rate of immediate complete occlusion was higher in the TV and SOV cohorts than in the TA cohort while the rate of complete occlusion at final follow-up was highest in the SOV cohort. The SOV approach was significantly associated with higher rates of postoperative complications. Indirect CCFs require careful examination of the fistulous point and the venous drainage to provide the most effective patient-tailored approach.
The invention relates to the technical field of medicines, in particular to a quzhazhigan long-circulating liposome and a preparation method thereof. The Quzhazhigan long-circulating liposome provided by the invention comprises Quzhazhigan, phospholipid, cholesterol and Tween-80. Also comprises a freeze-drying protective agent lactose. The formula is reasonable, and the encapsulation and the controlled release of the medicine can be realized. In addition, the invention also provides a preparation method of the Quzhazhigan long-circulating liposome, and the process adopts a film dispersion method, is simple to operate and has proper parameters, so that ideal encapsulation efficiency and liposome morphology are obtained. Experiments show that the liposome provided by the invention is spherical or sphere-like under a transmission electron microscope, has good dispersibility, a Zeta potential of-39.34 mV, an average particle size of 161.95nm, a dispersion index PDI of 0.3097 and an entrapment rate of 54.5%. After freeze-drying and rehydration, the properties are still stable.
In patients with renal insufficiency, acute renal failure requiring dialysis or worsening renal function have occurred, mostly within 48 hours of OMNISCAN Injection. The risk of renal failure may increase with increasing dose of gadolinium contrast. Use the lowest necessary dose of contrast and evaluate renal function in patients with renal insufficiency. Acute renal failure was observed in < 1% of patients in OMNISCAN clinical studies [see Adverse Reactions (6)].

OMNISCAN is cleared by glomerular filtration. Hemodialysis also enhances OMNISCAN clearance [see Use in Specific Populations (8.5, 8.6)].
Patients will be treated with pembrolizumab and intravenous peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate (177Lu-DOTATATE, Lutathera®) for up to four (4) sessions. Patients with somatostatin receptor positive (SSTR+) tumors with Ki-67 index \> 20% (well-differentiated grade 3) and any number of liver and/or extrahepatic lesions with liver parenchyma replacement by tumor \< 75%. Patients who achieve progressive or stable disease response after cycle 4 may receive an additional 4 cycles of pembrolizumab and lutetium Lu-177 DOTATATE in the absence of disease progression or unacceptable toxicity and pembrolizumab for up to 35 cycles.
The invention discloses 3 kinds of recombinant adenovirus, RBD of SARS-CoV-2 Spike protein and their application. The present invention provides recombinant adenoviruses: expressing the recombinant adenovirus of the protein shown in the sequence 3 of the sequence table; expressing the recombinant adenovirus of the protein shown in the sequence 5 of the sequence table; a recombinant adenovirus expressing the protein shown in the sequence 1 of the sequence table. The protein shown in the sequence 1 of the sequence table is the full-length SARS-CoV-2 Spike protein. The protein shown in sequence 3 of the sequence table is the SARS-CoV-2 receptor binding domain RBD protein with membrane anchoring signal peptide. The protein shown in the sequence 5 of the sequence table is SARS-CoV-2 receptor binding domain RBD protein with secretory signal peptide. The vaccine developed by the invention aiming at the novel coronavirus SARS-CoV-2 has important theoretical guidance value and wide application prospect, and provides possibility for radical treatment of the novel coronavirus pneumonia.
An MSP platform provides contingent healthcare worker recruiting and shift assignation in a multilayered process of job order broadcasting, competency matching, proposals from healthcare agencies aka vendors, screening, compliance management, and onboard of each candidate. Each staff profile submitted has to go through multilayered review, approval, and orientation process. Additionally, each healthcare worker's calendar, credential, and compliance have to be managed across multiple employers to prevent scheduling conflict and compliance violations, and guaranteeing full visibility of all healthcare workers across the entire supply chain. MSPs (Managed Service Providers) have the ability to service a large number of facilities on whose behalf the MSPs generate job orders for contingent workforce, and manage fulfillment using suppliers (aka vendors) mapped to the facility being serviced. The supplier ecosystem is a cohesive block that may be shared across all MSPs, and several such MSP ecosystems should be allowed to coexist in the system. Suppliers can be tiered by geography allowing a large vendor network to track demand from one or more healthcare facilities across a single location or a group of vendor locations. Additionally, a facility that is part of an MSP should also be able to work directly with all suppliers either in conjunction with or independent of an MSP. Both long term assignments referred to as ‘Travel’ position, and on-demand shift assignments referred to as ‘Day-to-day’ position are serviceable under this centrally available software commonly referred to as ‘Software as a Service’.
.[.A pharmaceutical composition comprises a synergistic combination of about 0.01-0.15% by wt. triamcinolone acetonide and about 0.04-0.3% by wt. halcinonide as active ingredients, in combination with a pharmaceutically acceptable carrier..]. 
     .Iadd.A pharmaceutical composition comprises a synergistic combination of at least about 0.01% by wt. triamcinolone acetonide and at least about 0.01% by wt. halcinonide as active ingredients therein, in combination with a pharmaceutically acceptable carrier. .Iaddend.
BACKGROUND: Colon adenocarcinoma (COAD) is a prevalent malignant tumor globally, contributing significantly to cancer-related mortality. COAD guidelines label MSI (Microsatellite instability) and MSS (Microsatellite stability) subtypes as global classification criteria and treatment strategy selection criteria for COAD. Various combination therapies involving PD-L1 inhibitors and adjuvant therapy to enhance anti-tumor efficacy.
METHODS: Datasets from single-cell RNA sequencing and bulk RNA sequencing in the TCGA and GEO databases were utilized to identify differentially expressed genes (DEGs). Furthermore, the correlation between ATP8B3 and PD-L1 was validated using siRNA, shRNA, and western blot analysis. Additionally, the association between ATP8B3 and immune checkpoint blockade (ICB) therapy was investigated through immune infiltration analysis and flow cytometry in both in vivo and in vitro assays.
RESULTS: In the COAD patient group, ATP8B3 significantly contributed to the establishment of an immunosuppressive microenvironment. Inhibiting ATP8B3 led to a reduction in PD-L1 expression in colon cancer cell lines. Additionally, ATP8B3 expression levels could serve as a potential guide for PD-L1 treatment in MSI-H COAD patients, with higher ATP8B3 expression associated with increased sensitivity to PD-L1 therapy. However, due to the lack of immuno-killer cells in the microenvironment of MSS subtypes, elevated ATP8B3 expression couldn't increase the sensitivity of MSS COAD patients to PD-L1 inhibitors.
CONCLUSION: Our research results support that Inhibiting ATP8B3 could enhance TIL (tumor-infiltrating lymphocyte) infiltration by reducing PD-L1 expression in MSI-H COAD, thereby serving as an effective strategy to improve PD-L1 blocker efficacy. The treatment strategy of combining ATP8B3 inhibitors and immunotherapy for MSI/MSS COAD patients will be the best choice.